Avenue Therapeutics, Inc. Common Stock
ATXI
ATXI was delisted on the 18th of March, 2025.
11 hedge funds and large institutions have $849K invested in Avenue Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.
59% more capital invested
Capital invested by funds: $533K → $849K (+$317K)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
15% less funds holding
Funds holding: 13 → 11 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$300K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$45.2K |
| 3 |
SAM
Shikiar Asset Management
New York
|
+$16.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IWP
Icon Wealth Partners
Houston,
Texas
|
-$46.6K |
| 2 |
Renaissance Technologies
New York
|
-$19K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.64K |
| 4 |
Bank of New York Mellon
New York
|
-$494 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $647K | +$300K | +3,646 | +98% |
|
|
2
Bank of New York Mellon
New York
| $62K | -$494 | -6 | -0.8% |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $60.5K | +$45.2K | +549 | +361% |
|
4
State Street
Boston,
Massachusetts
| $35.2K | – | – | – |
|
|
SAM
5
Shikiar Asset Management
New York
| $29K | +$16.5K | +200 | +150% |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $6.59K | -$2.64K | -32 | -30% |
|
7
Wells Fargo
San Francisco,
California
| $5.37K | – | – | – |
|
8
BlackRock
New York
| $2.27K | – | – | – |
|
|
EL
9
EMFO LLC
Weston,
Florida
| $624 | – | – | – |
|
10
Morgan Stanley
New York
| $484 | – | – | – |
|
|
BC
11
Barrett & Company
Providence,
Rhode Island
| $17 | – | – | – |
|
|
IWP
12
Icon Wealth Partners
Houston,
Texas
| – | -$46.6K | -533 | Closed |
|
|
13
Renaissance Technologies
New York
| – | -$19K | -213 | Closed |
|
ATXI Hedge Fund Activity: Q2 2023 in Review
11 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q2 2023, worth a combined $849K — up 59% from $533K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ATXI and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was Sabby Management, adding an estimated $300K. The largest seller was Icon Wealth Partners, exiting entirely with an estimated $46.6K sold.
- 11 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q2 2023, down from 13 in Q1 2023.
- Funds reported $849K of Avenue Therapeutics, Inc. Common Stock stock for Q2 2023, up 59% quarter-over-quarter.
- 0 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q2 2023 and 2 closed out, a net change of -2 holders.
- The largest Avenue Therapeutics, Inc. Common Stock buyer in Q2 2023 was Sabby Management, an estimated $300K added.
- The largest Avenue Therapeutics, Inc. Common Stock seller in Q2 2023 was Icon Wealth Partners, an estimated $46.6K sold.
Based on aggregated 13F filings for Q2 2023.